Registered outcomes11

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 11 of 11

List	Outcome	Time frame	Description
Primary	Incidence and severity of AE	Up to follow-up period, approximately 24 months	Phase 1b
Primary	Dose Limiting Toxicity (DLT)	approximately 24 months	Phase 1b
Primary	Maximal Tolerable Dose (MTD)	approximately 24 months	Phase 1b
Primary	Phase III Recommended Dose (RP3D)	approximately 24 months	Phase 1b
Primary	Progression-free survival (PFS) assessed by blind Independent Center Review (BICR) based on RECIST 1.1 criteria	approximately 36 months	Phase 3
Secondary	SHR-A1904 toxin binding antibody	approximately 24 months	Phase 1b
Secondary	SHR-A1904 Total antibody	approximately 24 months	Phase 1b
Secondary	Immunogenicity indicators of SHR-A1904: drug resistant antibody (ADA) and neutralizing antibody (NAb)	approximately 24 months	Phase 1b
Secondary	Expression level of CLDN18.2 in tumor tissues	approximately 24 months	Phase 1b
Secondary	Overall survival (OS)	approximately 36 months	Phase 3
Secondary	Incidence and severity of AE	approximately 36 months	Phase 3

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT06350006/registered